Post remission consolidation by autologous HCT for AML in CR1, negative implications for subsequent allogeneic HCT in CR2. A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

During the past decades, autologous hematopoietic cell transplantation (HCT) has been widely used as consolidation treatment in patients with acute myeloid leukemia (AML) in first or second complete remission (CR) [1 –11]. Over time, donors for allogeneic stem cell transplantation have become available and allogeneic HCT appears to have in part replaced autologous HCT.

Source: Biology of Blood and Marrow Transplantation - November 19, 2019 Category: Hematology Authors: J.R. Passweg, M. Labopin, M. Christopeit, J. Cornelissen, T. Pabst, G. Soci é, N. Russel, I. Yakoub-Agha, D. Blaise, T. Gedde-Dahl, H. Labussière-Wallet, R Malladi, E Forcade, S. Maury, E. Polge, F. Lanza, N.C. Gorin, M. Mohty, A. Nagler Source Type: research